Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples